Antimicrobial treatment guidelines for acute bacterial rhinosinusitis.
Anon
Jack B
JB
University of Pittsburgh, School of Medicine, USA.
Jacobs
Michael R
MR
Poole
Michael D
MD
Ambrose
Paul G
PG
Benninger
Mark S
MS
Hadley
James A
JA
Craig
William A
WA
D000208:Acute Disease; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D024841:Fluoroquinolones / Q000494:pharmacology / Q000627:therapeutic use; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D007769:Lactams / Q000627:therapeutic use; D018942:Macrolides / Q000494:pharmacology / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D009010:Monte Carlo Method; D001936:Moraxella catarrhalis / Q000187:drug effects; D009305:Nasopharynx / Q000382:microbiology; D010033:Otitis Media / Q000188:drug therapy; D012220:Rhinitis / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D012852:Sinusitis / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D007769:Lactams; D018942:Macrolides